Microsoft Word web i\347in rehber son doc
Yüklə 241,46 Kb. Pdf görüntüsü
|
|
23
Tehlikeli İlaç Kriterlerine Uygun Olarak Hazırlanan İlaç Listesi – NİOSH (National Institute for Occupational Safety and Health)-2003 Aldesleukin Alemtuzumab Altretamine Amsacrine Anastrozole Arsenic trioxide Asparaginase Azacitidine Azathioprine Bexarotene Bicalutamide Bleomycin Busulfan
Capecitabine Carboplatin Carmustine Chlorambucil Cisplatin Cladribine Cyclophosphamide Cytarabine Cyclosporin Dacarbazine Dactinomycin Daunorubicin HCl Denileukin Docetaxel Doxorubicin Epirubicin Estramustine phosphate sodium
Etoposide Exemestane Floxuridine Fludarabine Fluorouracil Flutamide Fulvestrant Gemcitabine Gemtuzumab ozogamicin
Goserelin Hydroxyurea Ibritumomab tiuxetan
Idarubicin Ifosfamide Imatinib mesylate Interferon alfa-2a Interferon alfa-2b Interferon alfa-n1 Interferon alfa-n3 Irinotecan HCl Leflunomide Letrozole Leuprolide acetate
Lomustine Mechlorethamine Megestrol Melphalan Mercaptopurine Methotrexate Mitomycin Mitotane
Mitoxantrone HCl Nilutamide Oxaliplatin Paclitaxel Pegaspargase Pentostatin Perphosphamide Pipobroman Piritrexim isethionate
Plicamycin Prednimustine Procarbazine Raltitrexed Streptozocin Tamoxifen Temozolomide Teniposide Testolactone Thioguanine Thiotepa
Topotecan Toremifene citrate Tositumomab Triptorelin Uracil mustard Valrubicin Vinblastine sulfate Vincristine sulfate Vindesine Vinorelbine tartrate
Sürekli yeni çalışmalar yapılıp yeni ilaçlar bulunduğu için bu liste belli aralıklarla güncelleştirilmelidir. 24
FDA (U.S.Food and Drug Administration) Tarafından Yeni Onaylanmış Tehlikeli İlaçlar Aripiprazol Valproate Na Eszopicline Lenalidomide Erlotinib Hcı Pemetrexed Valproic Acid Pregagalin Risperidone Tinidazole Alafacept Divalproex Na Strontium-89 Chloride Risperidone Bosentan Lubiprostone Medroxyprogesterone Micafungin Sodyum Rituximab Oxcarbazepine Apomorphine Hcl Pimecrolimus Alglucuside Alfa Ramelteon Azacitidine Nelarabine Cetuximab Sorafenib Quetiapine Fumerate Nevirapine Bevacizumab Ziprasidone Abatacept Titropium Bromid
Tenofovir Rasagiline Mesylate İ matinib Mesylate Paroxetine Hcı Titropium Bromide Trypan Blue Entecavir Zalcitibine Pentetate Kalsiyumb Trisodyum Dasantinib Vorinostat Varenicline Topotecan Hcı Profimer Sodyum Sutent
Zonisamide Clofarabine Mecasermin Medroxyprogesteron Efavirenz Amidarone Hcl Palifermin Samarium 153 Sunitib Malate
Decitibine Cladrabine Sirolimus 153 Tracleer
25
1.
American Society of Health-System Pharmacist. ASHP Guidlines on Handling Hazardous Drugs. 2006;63:1172–1193 2. American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs,1996. 3.
Anwar,W.A.,Salama,S.I.,El Serafy,M.M.,Hemida,S.A.,Hafez,A.S.: Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs.
4.
Barbara G. Valanıs, Wıllıam M, Vollmer, Karen T, Labuhn, and Andrew G Glass, Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel,
5.
Bayhan,A., Burgaz,S., Karakaya,A.E.: Urinary thioether excretion in nurses at an oncologic department. J.Clin.Pharm.Therap., 12, 303-6,1987 6.
Burgaz,S., Karahalil,B., Canlı,Z., Terzioğlu,F., Ançel,G., Anzion,R.B.M., Bos,R., Hüttner,E.: Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations.
21(3),baskıda,2002. 7. Burgaz,S.,Karahalil,B.,Bayrak,P.,Taşkın,L.,Yavuzaslan,F., Bökesoy,I., Anzion,R.B.M., Bos,R.P., Platin,N: Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics.
8.
Burgaz,S.,Özdamar,Y.N.,Karakaya,A.E.:A signal assay for the detection of genotoxic compounds: Application on the of cancer patients on chemotherapy and of nurses handling cytotoxic drugs
9.
Connor T.H., McDiarmid M.A., Preventing occupational Exposures to Antineoplastic Drugs in Health Care Settings, CA Cancer J Clin 2006;56:354-365 10. Connor TH, Anderson RW, Sessink PJ, Broadfield L., Power La, Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States,
11. Connor TH., Permeability testing of glove materials for use with cancer chemotherapy drugs,
12. Cornetta T, Padua L, Testa A, Ievoli E, Festa F, Tranfo G, Baccelliere L, Cozzi R.:Molecular biomonitoring of a population of nurses handling antineoplastic drugs
13. Cytotoxic Drug Safe Work Procedure, www.cariboo.bc.ca/hsafety/scp/cytotoxic.htm
14. Ensslin,A.S.,Huber,R.,Pethran, A., Römmelt, H.,Schierl,R.,Kulka,U.,Fruhmann,G.: Biological monitoring of hospital pharmacy personnel occupationally exposed to 26 cytostatic drugs: urinary excretion and cytogenetic studies. Int. Arch.Occup.Environ. Health, 70, 205–8, 1997. 15. Fransman W.,Vermeulen R., Kromhout H: Dermal exposure to cyclophosphamide in hospitals during preparation,nursing and cleaning activities.Int Arch Occup Environ Health 78: 403–412, 2005. 16. Fuchs, J., Hengstler, J.G., Jung, D., Hiltl,G., Konietzko,J., Oesch,F.:DNA damage in nurses handling antineoplastic agents. Mutat.Res.,342,17-23, 1995. 17. Fucic,A.,Jazbec,A., Mijic, A, Seso-Simic,D., Tomek,R.: Cytogenetic consequences after occupational exposure to antineoplastic drugs.
18. Griffin E (2003) Safety considerations and safe handling of oral chemotherapy agents. Clin J Oncol Nurs, 7 (suppl 6):25-29. 19. Grummt,T., Grummt,H.J., Schott,G.: Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs.
302,19-24,1993. 20. Gullo M, S, Safe Handling of Cytotoxic Agents Safe Handling of Antineoplastic Drugs:
21. Gündoğdu F, Karadağ A, Kav S, Taşkın L, Terzioğlu F, Ünlü H, Yavuzarslan F.: Onkoloji Alanında Çalışan Hemşirelerin Bireysel Özellikleri, Çalışma Koşulları ve Rollerine Uygun İşlevlerini Belirlemek, 30.06.2002, Oslo, Norveç’te yapılan 18. UICC Uluslar arası Kanser Kongresi’nde sözel bildiri olarak sunulmuştur. 22. Harrison BR, Peters BG, Bing MR, Comparison of surface Contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus Standard preparation techniques, Am J Health Sysy Pharm.2006,Sep 15;63(18):1736– 44 23. Hemminki,K., Kyyronen,P., Lindbohm,M.L.: Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases,cytostatic drugs and other potential hazards in hospitals, based on registered information of outcome. J.Epidemiol, Community Health, 39,141–147,1985. 24. Hirst,M.,Tse,S.,Mills,D.G.,Levin.: Occupational exposure to cyclophosphamide. Lancet, January 28,186–88,1984. 25. İSOOP,
26. Jackson CA., Wilson DA., World at work: Hospital pharmacy clean rooms, Occupational and Enviromental Medicine 2006;63:68-70 27. Jagun,O.,Ryan,M.,Waldron,H.A.: Urinary thioether excretion in nurses handling cytotoxic Drugs.
28. Jakab,M.G., Major,J., Tompa,A.: Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs,
29. James A. Jorgenson, Susan M. Spivey, David Canan, Howard Ritter, Bart Smith, Contamination Comparison of Transfer Devices Intended for Handling Hazardous
27 Drugs, Vlome 43, Number 9, pp 723-727 2008 Wolters Kluwer Health, Hospital Pharmacy. 30. Karahalil B.,Akkoyunlu İlter K.: Determination of urinary cyclophosphamide in oncology nurses handling antineoplastic drugs
by gas
chromatography-mass spectrometry.FABAD J.Pharm.Sci.,28:125-130,2003. 31. Kasuba,V., Rozgaj, R, Garaj-Vrhovac, V.: Analysis of sister chromatid exchange and micronuclei in peripheral blood lymphocytes of nurses handling cytostatic drugs. J.Appl.Toxicol.,19(6), 401-4, 1999. 32. Kösgeroğlu N., Ayrancı U., Özerdoğan N., demirustu C., Turkish nurses’information about, and administration of chemotherapeutic drugs, J Clin Nurs, 2006 Sep;15(9):1179-87 33. Kubilay,G., Fesci,H., Erdem,Y., Yurtsever,S., Kutlutürkan,S., Güner,P.,Platin,N.: Kemoterapi hazırlayan ve uygulayan hemşirelere ilişkin durum değerlendirmesi. Onkoloji Hemşireliği Derneği Bülteni, 6,7–15,1997. 34. Larissa C. Singleton and Thomas H. Connor.: An Evaluation of the Permeability of Chemotherapy Drugs,
35. Margolis CZ, Cretin s.(Eds.) Implementing Clinical Practice Guidelines, AHA, 1999, Margolis CZ. “Developing and Constructing Practical Guidelines”. 36. Martin S., The adverse health effects of occupational exposure to hazardous drugs, Vol.2/Number 5 September/october 2005, Community Oncology, 397-400 37. NIOSH ALERT, Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings, PUBLİCATİON NUMBER 2004-165, September 2004. www.cdc.gov/niosh
38. Norppa,H.,Sorsa,M.,Vainio,H.,Gröhn,P.,Heinonen,E.,Holsti,L.,Nordman,E.: Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs.
Scand.J.Work Environ.Health, 6,299-301,1980. 39. Occupational Health and Safety Administration, OSHA Instruction TED 1.15. Directorate of Technical Support. Controlling Occupational exposure to Hazardous Drugs.,March 2001. 40. Oestreicher,U.,Stephan,G.,Glatzel,M.: Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat.Res.,242,271-77,1990. 41. Paul J. M. Sessink, Mary-Ann E. Rolf, N. Stefan Ryden, Evaluation of the PhaSeal Hazardous Drug Containment System, Hospital Pharmacy, Vol. 34 No. 11, pp 1311- 1317, November 1999. 42. Pilger A.,Köhler,I.,Stettner,H., Mader,R.M., Rizovski, Terkola,R., Diem,E., Franz- Hainzl,E., Konnaris,C., Valic,E., Rüdiger,H.W.: Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel
28 occupationally exposed to cytostatic drugs, Int.Arch.Occup.Environ.Health, 73,442- 448,2000. 43. Platin N., Dokuz Yıllık Çalışmanın Sonucu, Onkoloji Hemşireliği Derneği Bülteni No: 23, 2004
44. Pohlova,H., Cerna,M., Rössner,P. : Chromosomal aberration, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat. Res., 174, 213-17,1986. 45. Polovich M., Developing a hazardous drug safety handling program, Volume 2/Number 5 September/October 2005, community Oncology 403-405 46. Polovich M., Safe Handling Hazardous Drugs, Nursing World/OJİN, September 30, 2004.
www.nursingworld.org/ojin/topic
47. Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Grover P.: Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis,22(6):395–401, 2007. 48. Sarto, F., Trevison, A., Tomanin, R., Canova, A., Fiorentino, M.: Chromosomal aberrations, sister chromatid exchanges, and urinary thiothers in nurses handling antineoplastic drugs.
49. Selevan,S.G., Lindbohm,M.L., Hornung,R.W., Hemminki,K: A study of occupational exposure to antineoplastic drugs and fetal loss in nurses.
1178,1985. 50. Sessink, P.J.M., Boer,K.A.,Scheefhals,A.P.H.,Anzion,R.B.M., Bos,R.P.: Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and iphosphamide in urine of exposed workers. Int.Arch.Occup. Environ. Health., 64,105-12, 1992. 51. Sessink, P.J.M., van de Kerkhof, M.C.A.,. Anzion, R.B.M, Noordheek, J., Bos,R.P.: Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians : Is skin absorption an important exposure route?,
52. Sessink.,P.J.M., Cerna ,M., Rössner ,P., Pastorkova ,A., Bavarova ,H.,. Frankova ,K, Anzion, R.B.M., Bos, R.P.: Urinary cyclophosphamide excretion and chromosomal aberratios in peripheral blood lymphocytes after occupational exposure to antineoplastic agents,
53. Sherins,J.J.,De Vita,V.T.: Effect of drug treatment for lymphoma on male reproductive capacity.
54. Sorsa, M., Hameila, M., Jarviluoma, E., Handling Anticancer Drugs From Hazard Identification to Risk Management? Ann. N.Y. Acad. Sci. 1076: 628–634, 2006. 55. Sorsa,M.,Pyy, L.,Salomaa,S., Nylund, L., Yager,J.W.: Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals.
29 56. Sotaniemi,E.A.,Sutinen,S., Arranto,A.J.: Liver damage in nurses handling cytostatic agents. Acta Med.Scand, 214,181-189,1983. 57. Spivey S., Connor T., Determining Sources of Workplace Contamination with Antineoplastic Drugs and Comparing Conventional IV Drug Preparation with a Closed System, Hospital Pharmacy, Vol.38 No.2, 135-139, February 2003. 58. Susan Spivey, Thomas H. Connor, Determining Sources of Workplace Contamination with Antineoplastic Drugs and Comparing Conventional IV Drug Preparation with a Closed System, Hospital Pharmacy, Vol. 38, No.2, February 2003. 59. ardaş,S., Gök,S., Karakaya,A.E.: Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs.
60. Tuncer M., Burgaz S., Çay .F., Dağlı M., Gündoğdu F., Özkan A., Bozkurt S., Kılıç H., Bayraktar G., Gündüz M., Ardıç A., Yanıkoğlu İ., (Antineoplastik –sitotoksik – İlaçlarla Güvenli Çalışma Rehberi Komisyonu ve Yayın Grubu), T.C. Sağlık Bakanlığı Tedavi Hizmetleri Genel Müdürlüğü Antineoplastik (sitotoksik) İlaçlarla Güvenli Çalışma Rehberi Ankara, 2003, Onkoloji Hemşireliği Derneği Bülteni No:23,2004 61. Ündeğer Ü, Başaran N, Kars A, Güç D.: Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat.Res., 439, 277- 85,1999. 62. Welch J, Silveira J.M., Safe handling of Cytotoxic Drugs: An Independent Study Module, 2 nd: Pittsburgh (PA): Oncology Nursing Society; 1997.26 p. 63. Wick C, Slawson MH., Jorgenson JA., et al. Using a closed-system protective device to reduce personal exposure to antineoplastic agents. Am J Health-Syst Pharma . 2003;60:2314–20. 64. Yaakov C., Isaac S., 25 years of safe handling of cytotoxics (antineoplastics) in İsrael, Journal of Onkology Pharmacy Practice Vol.12, No.2, 83-90,2006. 65. Yasko J.M.,
Mary A. McLaughlin, Cytotoxic Safety Precautions 1-9, 5 th edition, , Pittsburgh, 2001 30
Alanında Uygulama Rehberlerinin Oluşturulması, Kullanımının Yaygınlaştırılması ve İzlenmesi Çalışma Grubu Üyeleri (Rehber 2009) Rehberin yenilenmesi çalışmalarına başlamadan önce 2003 yılında rehberi hazırlayan “Standart Geliştirme Grubu” üyelerine ulaşılmış ve rehberin yenilenme sürecine katılmak isteyip istemedikleri sorulmuştur. Katılanlarla birlikte yeni rehber grubumuz aşağıdaki kişilerden oluşmuştur; Başkan
Hem. Filiz ÇOLAK Hacettepe Üniversitesi Onkoloji Hastanesi Hem. Burçin ORAK Hacettepe Üniversitesi Onkoloji Hastanesi
Hem. Kıymet AKGEDİK Özel Medicana Internatıonal Ankara Hastanesi Sekreter
Hem. Gülder GÜMÜKAYA Hem. Elif KAYA Hacettepe Üniversitesi Onkoloji Hastanesi Hacettepe Üniversitesi Onkoloji Hastanesi
Uzm. Hem. Fatma GÜNDOĞDU Özel Medicana Internatıonal Ankara Hastanesi Hem. Sevgi ERDAL Hacettepe Üniversitesi Onkoloji Hastanesi Hem. Meral BAKAR Ankara Numune Eğitim ve Araştırma Hastanesi Hem. Yeter KIRDAL Hacettepe Üniversitesi Üroonkoloji Ünitesi Hem. Mine Buluş Hacettepe Üniversitesi Erişkin Hastanesi
Prof.Dr. Sema Burgaz Gazi Ü. Ecz. Fak. Toksikoloji ABD Prof. Dr. Feray Gökdoğan Abant İzzet Baysal Üniversitesi Sağlık Yüksekokulu Prof. Dr. Ayfer Karadakovan Ege Üniversitesi İç Hastalıkları Hemşireliği Anabilim Dalı Doç.Dr. Sultan Kav Başkent Üniversitesi Sağlık Bilimleri Fakültesi Yard.Doç.Dr. Gülbeyaz Can İ stanbul Üniversitesi Florence Nightingale Hemşirelik Yüksekokulu Hem. Figen Karabay Gazi Üniversitesi Dahiliye Kliniği Hem. Meryem Aras Sağlık Bakanlığı Demetevler Onkoloji Hastanesi Hem. Aysel Enaboifo Özel Medicana Internatıonal Ankara Hastanesi
31
Bakım Standartlarının Oluşturulması Çalışma Grubu Üyeleri (Rehber 2003) Başkan
Doç. Dr. Kafiye Eroğlu Hacettepe Üniversitesi Hemşirelik Y.O. Doğum-Kadın Sağlığı ve Hastalıkları Hemşireliği ABD Yrd. Doç. Dr. Sibel Erkal Ankara Üniversitesi Cebeci Sağlık Yüksekokulu Sekreter
Hem. Ayşe Turgut
TCDD Ankara Hastanesi Hem. Yeter Kırdal Hacettepe Üniversitesi Üroonkoloji Ünitesi Üyeler
Prof. Dr. Sema Burgaz Gazi Üniversitesi Eczacılık Fakültesi Doç. Dr. Sıdıka Kaya Hacettepe Üniversitesi Sağlık İdaresi Yüksekokulu Doç. Dr.Nalan Albayrak GATA Hemşirelik Yüksekokulu Uzm. Hem. Fatma Gündoğdu Hacettepe Üniversitesi Onkoloji Hastanesi Hem. Asiye Özkan Ankara Üniversitesi İbn-i Sina Hastanesi Tıbbi Onkoloji Kliniği Hem. Sahra Urhan Hacettepe Üniversitesi KBB Kliniği Hem. Hatice Kılıç Sağlık Bakanlığı Demetevler Onkoloji Hastanesi Hem. Çiğdem Meral
Sağlık Bakanlığı Numune Eğitim ve Araştırma Hastanesi KİT Ünitesi Hem. Nursel Meriç
Ankara Universitesi İbn-i Sina Hastanesi Kemoterapi Gündüz Tedavi Ünitesi Nuran Erol Ankara Üniversitesi Cebeci Sağlık Yüksekokulu Meltem Yüksekcan Ankara Üniversitesi Cebeci Sağlık Yüksekokulu Yeliz Çakır Ankara Üniversitesi Cebeci Sağlık Yüksekokulu
Prof. Dr. Nurgün Platin Koç Üniversitesi Sağlık Yüksekokulu Prof. Dr. Nuran Akdemir Hacettepe Üniversitesi Hemşirelik Y.O. İç Hastalıkları Hemşireliği ABD Prof. Dr. Ayfer Karadakovan
Ege Üniversitesi İç Hastalıkları Hemşireliği Anabilim Dalı Prof. Dr. Ali Esat Karakaya Gazi Üniversitesi Eczacılık Fakültesi Prof. Dr. Tülin Bedük Ankara Üniversitesi Cebeci Sağlık Yüksekokulu Doç. Dr. Güler Çimete Marmara Üniversitesi Hemşirelik Yüksekokulu Doç. Dr. Feray Gökdoğan Abant İzzet Baysal Üniversitesi Sağlık Yüksekokulu Doç Dr. Hatice Fesci Gazi Üniversitesi Sağlık Yüksekokulu İç Hastalıkları Anabilim Dalı Uzm. Hem. Sultan Kav Hacettepe Üniversitesi Onkoloji Hastanesi Hem. Figen Karabay Gazi Üniversitesi Dâhiliye Kliniği Hem. Sevinç Yurtal Sağlık Bakanlığı Demetevler Onkoloji Hastanesi Yüklə 241,46 Kb. Dostları ilə paylaş:
|